Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

 

SPEAKER: The factor date after 70 is because, when they decided the trial and they decided the approach, they were in unknown area. That was the area where lower than 40, you didn't really know what would have happened. And we have to appreciate that. Nowadays, we know we can go as low as 10, but we didn't know at the time that things were designed. So the 70 was there in a way, also in the trial design of the Odyssey, just because there was uncertainty in that area.

But now, there is no reason anymore. I mean, it's a choice. If a physician feels to use the 75, it's fine. But we have sort of a biased view, in the sense that we are lipidologists, so we know that if we go low with the LDL, it's not the problem, but there is only a benefit. So we trust in data and we go.

Video

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis